natgillin/translations-raw huggingface dataset:
c Non-inferiority was tested using a pre-specified, fixed non-inferiority margin of 4% at Day 28 of Cycle 1. d Estimates were obtained from a Cox proportional hazards regression model. 
c Neinferiornost je provjerena pomoću prethodno specificirane fiksne granice neinferiornosti od 4% 28. dana ciklusa 1. d Procjene su dobivene pomoću Coxovog regresijskog modela proporcionalnog hazarda.
Other medicines and Quinsair 
Drugi lijekovi i Quinsair
Elderly patients and women may be more sensitive to QTc-prolonging medicinal products. 
Stariji bolesnici i žene mogu biti podložniji QT-prolongaciji uzrokovanoj lijekovima.
Quinsair can interfere with the effects of these medicines. 
Quinsair može utjecati na učinke tih lijekova.
4) Keeping the handset level, place the mouthpiece in your mouth and close your lips around it (Figure 3). 
4) Držeći uređaj u ravnini stavite usnik u usta i stisnute usne oko njega (slika 3).
These metabolites account for ˂ 5% of the dose following systemic administration and are excreted in urine. 
Na ove metabolite otpada ˂ 5% doze nakon sistemske primjene i izlučuju se urinom.
Your risk is increased if you are elderly (above 60 years of age), have received an organ transplant, have kidney problems or if you are being treated with corticosteroids. 
Rizik Vam je povećan ako ste starije dobi (stariji od 60 godina), imate presađen organ, tegobe s bubrezima ili se liječite kortikosteroidima.
Anxiety*, Depression* 
anksioznost*, depresija*
b LS Mean (SE). 
b Srednja LS (SE).
Following oral and intravenous administration, levofloxacin is eliminated relatively slowly from the plasma (t1/2: 6 to 8 hours). 
Nakon peroralne i intravenske primjene levofloksacin se relativno sporo eliminira iz plazme (t1/2: 6 do 8 sati).
- Difficulty in breathing which can range from mild to severe (bronchospasm). 
- teškoće s disanjem koje se mogu kretati od blagih do teških (bronhospazam)
Levofloxacin may inhibit the growth of Mycobacterium tuberculosis and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis. 
Levofloksacin može inhibirati rast Mycobacterium tuberculosis i stoga može dati lažno negativne rezultate kod bakteriološkog dokazivanja tuberkuloze.
- Seizures and convulsions 
- napadaje i konvulzije
When the treatment is complete, the controller will ‘beep' twice. 
Kad je tretman dovršen kontrolor će se oglasiti tonom dva puta.
The medicine comes in small 3 ml plastic ampoules. 
Lijek se isporučuje u malim plastičnim ampulama od 3 ml.
This should be connected to either an eBase Controller or an eFlow rapid Control Unit. 
On mora biti spojen na kontrolor protoka ili eBase Controller eFlow rapid Control Unit.
Reduced bacterial permeability (common in P. aeruginosa) and efflux mechanisms may also confer or contribute to resistance. 
Smanjena bakterijska permeabilnost (česta kod P. aeruginosa) i mehanizmi efluksa mogu također biti uzrok ili doprinijeti rezistenciji.
If the contents of the ampoule are swallowed, don't worry but tell your doctor as soon as possible. 
Ako se sadržaj ampule proguta, nemojte se brinuti ali se obratite svom liječniku što je prije moguće.
Psychotic reactions 
Psihotične reakcije
- Superinfections 
- superinfekcije
Pharmacotherapeutic group: antibacterials for systemic use, fluoroquinolones ATC code: J01MA12 
Farmakoterapijska skupina: antibakterijski lijekovi za sustavnu primjenu, fluorokinoloni ATK oznaka: J01MA12
- Do not swallow the liquid in the ampoule. 
- Tekućinu iz ampule nemojte progutati.
The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). 
Bubrežni klirens levofloksacina bio je smanjen cimetidinom (24%) i probenecidom (34%).
Any unused product must be thrown away. 
Sav neiskorišteni lijek mora se baciti.
Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations. 
Stoga je potreban oprez kada se fluorokinoloni, uključujući levofloksacin, koriste u tim populacijama.
Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. 
Ispitivanja na miševima pokazala su da levofloksacin ima fototoksičku aktivnost samo u vrlo visokim dozama.
Quinsair can cause changes to your heart rhythm, especially if you are taking any medicines to treat heart problems or low levels of potassium or magnesium in the blood. 
Quinsair može izazvati promjene Vašeg srčanog ritma, osobito ako uzimate lijekove za srce ili za snižavanje razine kalija ili magnezija u krvi.
MARKETING AUTHORISATION NUMBER(S) EU/1/14/973/001 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/14/973/001
Final study report - by Q2 2022. 
Konačno izvješće o rezultatu ispitivanja - 2. tromjesečje 2022.
In vitro studies demonstrated that inhibition of the key transporters associated with drug disposition in the kidney (organic anion-transporting polypeptide-1B1 (OATP1B1), OATP1B3, organic anion transporter-1 (OAT1), OAT3 and organic cationic transporter-2 (OCT2)) at exposures following inhalation of 240 mg levofloxacin twice daily is low. 
In vitro ispitivanja pokazala su da je inhibicija ključnih transportera povezanih s dispozicijom lijeka u bubregu (organskog anionskog transportnog polipeptida 1B1 (OATP1B1), OATP1B3, organskog anionskog transportera-1 (OAT1), OAT3 i organskog kationskog transportera -2 (OCT2)) pri ekspoziciji nakon inhalacije 240 mg levofloksacina dva puta dnevno niska.
If you use more Quinsair than you should 
Ako primijenite više Quinsaira nego što ste trebali
Pharmacokinetic parameter 
Farmakokinetički parametar
7) Once complete, open the medicine cap to ensure all of the medicine has been used. 
7) Nakon dovršetka, otvorite poklopac spremnika kako biste provjerili je li iskorišten sav lijek.
What Quinsair is and what it is used for What you need to know before you use Quinsair How to use Quinsair 
Što je Quinsair i za što se koristi Što morate znati prije nego počnete primjenjivati Quinsair Kako primjenjivati Quinsair
The parameters associated with the antibacterial effects of levofloxacin are the Cmax/MIC and AUC/MIC ratios (Cmax = maximum concentration at the site of infection, AUC = area under the curve and MIC = minimal inhibitory concentration). 
Parametri povezani s antibakterijskim učinkom levofloksacina su omjeri Cmax/MIC i AUC/MIC (Cmax = maksimalna koncentracija na mjestu infekcije, AUC = površina ispod krivulje i MIC = minimalna inhibitorna koncentracija).
if you have experienced a previous episode of aortic dissection (a tear in the aorta wall). 
ako ste već prethodno doživjeli epizodu disekcije aorte (razdvajanje stijenki aorte).
Ask the patient to inhale and exhale through the mouthpiece until the treatment is finished. 
Zatražite od bolesnika da udiše i izdiše kroz usnik dok tretman ne bude gotov.
It takes about 5 minutes to inhale the medicine using the nebuliser. 
Potrebno je oko 5 minuta da bi se lijek inhalirao pomoću sustava za inhalaciju.
* Adverse events with uncertain relatedness to Quinsair but which are known to be associated with systemic administration of levofloxacin and/or are plausibly associated with Quinsair and were reported more frequently than with placebo in clinical studies. 
* Štetni događaji koji se ne mogu sa sigurnošću povezati s Quinsairom, ali za koje je poznato da su povezani sa sistemskom primjenom levofloksacina i/ili su vjerojatno povezani s Quinsairom i u kliničkim ispitivanjima su prijavljeni češće nego u skupini placebo.
Hyposmia*, Somnolence* 
hipozmija*, somnolencija*
Levofloxacin is stereochemically stable and does not undergo chiral inversion. 
Levofloksacin je stereokemijski stabilan i ne podliježe kiralnoj inverziji.
• Uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia). 
• Nekorigiranog disbalansa elektrolita (npr. hipokalijemija, hipomagnezijemija).
In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. 
U bolesnika koji se liječe levofloksacinom, određivanje opijata u urinu može dati lažno pozitivne rezultate.
How do I prepare my Nebuliser System to inhale the medicine? 
Kako ću pripremiti svoju napravu Nebuliser System za inhalaciju lijeka?
You should avoid prolonged exposure to sunlight or strong sunlight and should not use sunbeds or any other UV lamps whilst using Quinsair and for 48 hours after stopping treatment. 
Morate izbjegavati produljeno izlaganje sunčevoj svjetlosti ili jaku sunčevu svjetlost i ne smijete koristiti solarij ili bilo koju UV-lampu svo vrijeme dok koristite Quinsair i 48 sati nakon prestanka liječenja.
Quinsair must not be used whilst pregnant or breast-feeding. 
Quinsair se ne smije koristiti tijekom trudnoće i dojenja.
How long do I use it for? 
Koliko ću dugo primjenjivati lijek?
The most frequently reported adverse reactions were cough/productive cough (54%), dysgeusia (30%) and fatigue/asthenia (25%). 
Najčešće prijavljene nuspojave bile su kašalj/produktivni kašalj (54%), disgeuzija (30%) i umor/astenija (25%).
It belongs to the group of antibiotics called fluoroquinolones. 
Pripada skupini antibiotika koje nazivamo fluorokinoloni.
Four ampoules are sealed in a foil sachet and each box contains 14 sachets. 
Četiri ampule zavarene su u vrećici od folije i svaka kutija sadrži 14 vrećica.
In very rare cases, these have progressed to suicidal thoughts and self-endangering behavioursometimes after only a single dose of levofloxacin (see section 4.8). 
U vrlo rijetkim slučajevima ove su reakcije progredirale do suicidalnih misli i samougrožavajućeg ponašanja - ponekad nakon samo jedne doze levofloksacina (vidjeti dio 4.8).
Inner box 
Unutarnja kutija
In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential. 
Testiranja in vivo (mikronukleus, razmjena sestrinskih kromatida, nepredviđena sinteza DNA, dominanti letalni testovi) nisu pokazali genotoksični potencijal.
Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. including angioedema and anaphylactic shock). 
Levofloksacin može uzrokovati ozbiljne, potencijalno fatalne reakcije preosjetljivosti (npr. koje uključuju angioedem i anafilaktički šok).
• Hypersensitivity to the active substance, other quinolones or to any of the excipients listed in section 6.1. 
• Preosjetljivost na djelatnu tvar, druge kinolone ili neku od pomoćnih tvari navedenih u dijelu 6.1.
The recommended dosage is 240 mg (one ampoule) administered by inhalation twice daily (see section 5.2). 
Preporučena doza je 240 mg (jedna ampula) primijenjena inhalacijom dva puta na dan (vidjeti dio 5.2).
Cross-resistance between levofloxacin and other fluoroquinolones is observed. 
Primjećena je unakrsna rezistencija između levofloksacina i drugih fluorokinolona.
Quinsair may make you feel dizzy, tired or weak, or cause problems with your eyesight. 
Quinsair Vam može izazvati omaglicu, umor ili slabost ili Vam može uzrokovati probleme s vidom.
Keep the Zirela Instructions for Use in a safe place as they give full details on assembling the device. 
Držite Upute za uporabu naprave Zirela na sigurnom mjestu jer se u njima nalazi detaljan opis kako sastaviti uređaj.
In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. 
Slično ostalim fluorokinolonima, levofloksacin je pokazao učinke na hrskavicu (izbočenja i udubljenja) u štakora i pasa.
Inhale the contents of one ampoule (240 mg) twice a day using the Zirela Nebuliser System. 
Inhalirajte sadržaj jedne ampule (240 mg) dva puta na dan pomoću naprave za inhalaciju Zirela Nebuliser System.
You use Quinsair every day for 28 days, then take a 28-day break, during which you do not inhale any Quinsair. 
Quinsair primjenjujte svaki dan tijekom 28 dana, zatim napravite pauzu od 28 dana tijekom koje nećete inhalirati Quinsair.
You may rarely experience symptoms of nerve damage (neuropathy) such as pain, burning, tingling, numbness and/or weakness especially in the feet and legs or hands and arms. 
Rijetko možete osjetiti simptome oštećenja živaca (neuropatije) kao što su bol, žarenje, trnci, utrnulost i/ili slabost osobito u stopalima i nogama ili šakama i rukama.
if you have been diagnosed with an enlargement or "bulge" of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm). 
ako vam je dijagnosticirano proširenje ili „napuhivanje“ velike krvne žile (aneurizma aorte ili aneurizma periferne velike krvne žile).
This is because both active substances are capable of blocking the renal tubular secretion of levofloxacin. 
To je zato što obje djelatne tvari imaju sposobnost blokiranja bubrežne tubularne sekrecije levofloksacina.
Furthermore, clinical data do not suggest interaction with P-glycoprotein (P-gp) substrates such as digoxin. 
Nadalje, klinički podaci ne upućuju na interakciju sa supstratima P-glikoproteina (P-gp) poput digoksina.
In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2) indicating that levofloxacin is not a CYP1A2 inhibitor. 
U ispitivanju farmakokinetičke interakcije, levofloksacin nije utjecao na farmakokinetiku teofilina (koji je probni supstrat CYP1A2) što ukazuje da levofloksacin nije inhibitor CYP1A2.
Bacteria can become resistant to treatment with an antibiotic over time. 
Bakterije mogu s vremenom postati rezistentne (otporne) na liječenje antibiotikom.
Stop using Quinsair and tell your doctor immediately: - if you experience pain, stiffness and/or swelling in your joints - if you develop problems with your liver. 
Prestanite primjenjivati Quinsair i odmah se obratite svom liječniku: - ako osjetite bol, ukočenost i/ili oticanje zglobova - ako Vam se jave problemi s jetrom.
At the first sign of pain or inflammation of a tendon (for example in your ankle, wrist, elbow, shoulder or knee), stop taking Quinsair, contact your doctor and rest the painful area. 
Kod prvog znaka boli ili upale tetive (na primjer, u gležnju, zapešću, laktu, ramenu ili koljenu), prestanite uzimati Quinsair, obratite se liječniku i poštedite bolno područje.
Press down and turn the cap clockwise as far as it will go (b, Figure 2). 
Pritisnite prema dolje i zakrenite poklopac do kraja u smjeru kazaljki na satu (b, slika 2).
Continue to inhale and exhale comfortably until the treatment is finished. 
Nastavite opušteno udisati i izdisati dok postupak ne bude gotov.
Reduced susceptibility to levofloxacin can also result from acquisition of plasmids encoding proteins that protect these targets from inhibition. 
Smanjena osjetljivost na levofloksacin može također biti rezultat preuzimanja plazmida koji kodiraju proteine koji štite ta ciljna mjesta od inhibicije.
Taking these medicines with Quinsair may lead to an increase in bleeding. 
Uzimanje ovih lijekova zajedno s Quinsairom može dovesti do pojačanog krvarenja.
Inflammation and ruptures of tendons may occur within the first 48 hours of treatment and even up to several months after stopping of Quinsair therapy. 
Upala i puknuće tetiva mogu nastati unutar prvih 48 sati liječenja pa sve do nekoliko mjeseci nakon prestanka liječenja lijekom Quinsair.
The Manufacturer's Instructions for Use will give full details on cleaning and disinfecting. 
U Uputama proizvođača za uporabu naći ćete detaljan opis čišćenja i dezinfekcije.
The use of inhaled medicinal products may induce a cough reflex. 
Primjena inhalacijskog lijeka može izazvati refleks kašlja.
It is important that you keep using the medicine twice a day during your 28 days on treatment and that you keep to the 28-days on, 28-days off cycle for as long as your doctor tells you to. 
Važno je da nastavite primjenjivati lijek dva puta na dan tijekom 28 dana terapije i da se pridržavate ciklusa od 28 dana terapije i 28 dana bez terapije onoliko dugo koliko Vam je to rekao liječnik.
Interference with laboratory tests 
Utjecaj na rezultate laboratorijskih pretraga
If you are treated with Quinsair, you may have a severe skin reaction such as blistering or lesions. 
Ako se liječite Quinsairom, možete imati teške kožne reakcije poput stvaranja mjehura i rana.
There is a limited amount of data from the use of levofloxacin in pregnant women. 
Količina podataka o primjeni levofloksacina u trudnica je ograničena.
Two randomised, double-blind, single-cycle, placebo-controlled clinical trials (Studies 204 and 207) in patients with CF chronically infected with P. aeruginosa were conducted. 
Provedena su dva randomizirana, dvostruko slijepa, jednociklusna, placebom kontrolirana ispitivanja (Ispitivanje 204 i Ispitivanje 207) na bolesnicima s CF i kroničnom infekcijom P. aeruginosa.
If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8). 
Ako se javi oslabljeni vid ili neki drugi učinak na oči, potrebno je odmah potražiti savjet specijalista za bolesti očiju (vidjeti dijelove 4.7 i 4.8).
A total of 88 patients received at least 1 dose of Quinsair in Study 209 (Extension Phase), 32 of these had received TIS and 56 of these had received Quinsair in the Core Phase. 
Ukupno 88 bolesnika primilo je najmanje 1 dozu Quinsaira u Ispitivanju 209 (produljena faza), 32 od njih je primilo TIS i 56 je primilo Quinsair u središnjoj fazi ispitivanja.
Levofloxacin is primarily excreted unchanged in the urine and metabolism is minimal (see section 5.2). 
Levofloksacin se primarno izlučuje nepromijenjen urinom i minimalno se metabolizira (vidjeti dio 5.2).
If you experience breathing difficulties after using Quinsair, your doctor may prescribe you an inhaler containing a bronchodilator medicine (e.g. salbutamol). 
Ako osjetite poteškoće s disanjem nakon primjene Quinsaira, Vaš Vam liječnik može propisati inhalator koji sadrži lijek bronhodilatator (npr. salbutamol).
Following systemic administration, there were no significant differences in levofloxacin pharmacokinetics between young and elderly subjects except those associated with age-related decreases in creatinine clearance. 
Nakon sistemske primjene nije bilo značajne razlike u farmakokinetici levofloksacina između mladih i starijih ispitanika osim one povezane sa sniženim klirensom kreatinina zbog dobi.
Inhaled steroids. 
Inhalacijski steroidi.
1) Make sure that the Zirela Nebuliser Handset is on a flat and stable surface. 
1) Provjerite da je naprava za inhalaciju Zirela Nebuliser Handset položena na ravnu i čvrstu površinu.
Keeping the handset level, place the mouthpiece in the patient's mouth making sure their lips are closed around it. 
Držeći uređaj u ravnini stavite usnik u usta bolesnika pazeći da su usne stisnute oko njega.
Study 209 (Core Phase) was a randomised, open-label, parallel group, active-controlled, non-inferiority study comparing Quinsair to tobramycin inhalation solution (TIS) over 3 treatment cycles. 
Ispitivanje 209 (središnja faza) bilo je randomizirano, otvoreno, aktivno kontrolirano ispitivanje neinferiornosti na paralelnim skupinama u kojem se Quinsair usporedio s otopinom tobramicina za inhaliranje (tobramycin inhalation solution - TIS) kroz 3 terapijska ciklusa.
Talk to your doctor if you have any concerns or questions about this. 
Obratite se svom liječniku ako ste zabrinuti ili imate pitanja u vezi s tim.
Inhale your medicine as follows: - 1 ampoule in the morning using the Zirela Nebuliser - 1 ampoule in the evening using the Zirela Nebuliser It is best to leave close to 12 hours between your doses. 
Inhalirajte lijek kako slijedi: - 1 ampula ujutro pomoću naprave za inhalaciju Zirela Nebuliser - 1 ampula navečer pomoću naprave za inhalaciju Zirela Nebuliser Najbolje je da između doza protekne točno 12 sati.
The mean post-dose sputum concentrations were approximately 500-1900 µg/ml and were approximately 400-1700 times higher than those observed in serum. 
Srednja koncentracija u sputumu nakon primijenjene doze bila je oko 500-1900 µg/ml i oko 400-1700 viša od onih primijećenih u serumu.
If you have used more Quinsair than you should, tell your doctor as soon as possible. 
Ako primijenite više Quinsaira nego što ste trebali, obratite se svom liječniku što je prije moguće.
Respiratory domain of Cystic Fibrosis Questionnaire - Revised (CFQ-R) 
Dio koji se odnosi na respiraciju revidiranog Upitnika o cističnoj fibrozi (Cystic Fibrosis Questionnaire - Revised - CFQR)
The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial DNA gyrase and topoisomerase IV enzymes. 
Mehanizam djelovanja levofloksacina i drugih fluorokinolonskih antimikrobnih lijekova uključuje inhibiciju bakterijskih enzima DNA-giraze i topoizomeraze IV.
Patients should not inhale the contents of more than one ampoule to compensate for the missed dose. 
Bolesnici ne smiju inhalirati sadržaj više od jedne ampule kako bi nadoknadili propuštenu dozu.
- A disease causing muscle weakness and fatigue called myasthenia gravis. 
- bolest koja uzrokuje mišićnu slabost i umor, a koja se naziva mijastenija gravis.
When do I use it? 
Kada da primijenim lijek?
Haemodialysis, including peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD), are not effective in removing levofloxacin from the body. 
Hemodijaliza, uključujući peritonealnu dijalizu i kontinuiranu ambulatornu peritonealnu dijalizu (CAPD), nisu učinkovite u odstranjivanju levofloksacina iz tijela.
How do I use the Zirela Nebuliser System? 
Kako ću koristiti napravu za inhalaciju Zirela Nebuliser System?
500 mg IV QD* 
500 mg i.v. QD*
- Check that your Zirela Nebuliser System works properly before starting your treatment. 
Vaša naprava za inhalaciju Zirela Nebuliser System ispravno radi prije nego započnete terapiju.
The outer carton box also contains one Zirela Nebuliser Handset packaged in its own carton box with the Manufacturer's Instruction for Use. 
Vanjska kartonska kutija sadrži također i jednu napravu za inhalaciju Zirela Nebuliser Handset pakiranu u vlastitoj kartonskoj kutiji s uputama proizvođača za uporabu.
Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development. 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja toksičnosti jednokratne doze, toksičnosti ponovljenih doza, kancerogenosti te reproduktivne i razvojne toksičnosti.
Median time to administration of anti-pseudomonal antimicrobials 
Medijan vremena do primjene antipseudomonalnog antimikrobnog lijeka
Some adverse reactions (e.g. fatigue, asthenia, visual disturbances, dizziness) may impair patient's ability to concentrate and react. 
Neke nuspojave (npr. umor, astenija, smetnje vida, omaglica) mogu negativno utjecati na bolesnikovu sposobnost koncentracije i reakcije.
Animal studies with levofloxacin do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). 
Ispitivanja levofloksacina na životinjama ne ukazuju na izravne ili neizravne štetne učinke u smislu reproduktivne toksičnosti (vidjeti dio 5.3).
Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. 
Bolesnici s latentnim ili stvarnim oštećenjem aktivnosti glukoza-6-fosfat-dehidrogenaze mogu biti skloni hemolitičkim reakcijama kada se liječe kinolonskim antibakterijskim tvarima.
Higher sputum concentrations were observed in adults compared to paediatric patients in Study 207; similar sputum concentrations were observed in adult and paediatric patients in Study 209. 
U Ispitivanju 207 primijećene su više koncentracije u sputumu u usporedbi s pedijatrijskim bolesnicima; slične koncentracije u sputumu odraslih i pedijatrijskih bolesnika primijećene su u Ispitivanju 209.